These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 22318669)
1. Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH). Joglekar MV; Quintana Diez PM; Marcus S; Qi R; Espinasse B; Wiesner MR; Pempe E; Liu J; Monroe DM; Arepally GM Thromb Haemost; 2012 Apr; 107(4):717-25. PubMed ID: 22318669 [TBL] [Abstract][Full Text] [Related]
2. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Krauel K; Hackbarth C; Fürll B; Greinacher A Blood; 2012 Feb; 119(5):1248-55. PubMed ID: 22049520 [TBL] [Abstract][Full Text] [Related]
3. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Rauova L; Poncz M; McKenzie SE; Reilly MP; Arepally G; Weisel JW; Nagaswami C; Cines DB; Sachais BS Blood; 2005 Jan; 105(1):131-8. PubMed ID: 15304392 [TBL] [Abstract][Full Text] [Related]
4. Partially desulfated heparin modulates the interaction between anti-protamine/heparin antibodies and platelets. Jouni R; Zöllner H; Khadour A; Wesche J; Grotevendt A; Brandt S; Delcea M; Krauel K; Schwertz H; Sachs UJ; Greinacher A; Bakchoul T Thromb Haemost; 2016 Jan; 115(2):324-32. PubMed ID: 26423467 [TBL] [Abstract][Full Text] [Related]
5. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226 [TBL] [Abstract][Full Text] [Related]
13. Low anticoagulant heparin blocks thrombin-induced endothelial permeability in a PAR-dependent manner. Gonzales JN; Kim KM; Zemskova MA; Rafikov R; Heeke B; Varn MN; Black S; Kennedy TP; Verin AD; Zemskov EA Vascul Pharmacol; 2014 Aug; 62(2):63-71. PubMed ID: 24469066 [TBL] [Abstract][Full Text] [Related]
14. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Rauova L; Zhai L; Kowalska MA; Arepally GM; Cines DB; Poncz M Blood; 2006 Mar; 107(6):2346-53. PubMed ID: 16304054 [TBL] [Abstract][Full Text] [Related]
15. Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT. Kowalska MA; Krishnaswamy S; Rauova L; Zhai L; Hayes V; Amirikian K; Esko JD; Bougie DW; Aster RH; Cines DB; Poncz M Blood; 2011 Sep; 118(10):2882-8. PubMed ID: 21772054 [TBL] [Abstract][Full Text] [Related]
16. Physicochemical Characteristics of Platelet Factor 4 under Various Conditions are Relevant for Heparin-Induced Thrombocytopenia Testing. Bui VC; Gebicka P; Hippe H; Raschke R; Nguyen TL; Greinacher A; Nguyen TH J Phys Chem B; 2020 Feb; 124(8):1438-1443. PubMed ID: 31944769 [TBL] [Abstract][Full Text] [Related]
17. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Warkentin TE; Cook RJ; Marder VJ; Sheppard JA; Moore JC; Eriksson BI; Greinacher A; Kelton JG Blood; 2005 Dec; 106(12):3791-6. PubMed ID: 16109780 [TBL] [Abstract][Full Text] [Related]
18. Characterisation of the conformational changes in platelet factor 4 induced by polyanions: towards in vitro prediction of antigenicity. Brandt S; Krauel K; Gottschalk KE; Renné T; Helm CA; Greinacher A; Block S Thromb Haemost; 2014 Jul; 112(1):53-64. PubMed ID: 24671506 [TBL] [Abstract][Full Text] [Related]
19. Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia. Horne MK; Hutchison KJ Am J Hematol; 1998 May; 58(1):24-30. PubMed ID: 9590145 [TBL] [Abstract][Full Text] [Related]
20. Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT. Krauel K; Preuße P; Warkentin TE; Trabhardt C; Brandt S; Jensch I; Mandelkow M; Hammer E; Hammerschmidt S; Greinacher A Blood; 2019 Feb; 133(9):978-989. PubMed ID: 30573633 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]